Botulinum toxin for cerebral palsy; where are we now?
In this article, the evidence base for botulinum-A treatment acquired in recent years is outlined, and the practicalities involved in providing this service are described. Botulinum-A is relatively new, and possible improvements for the future are considered.
Morton
R E
RE
Ronnie MacKeith Child Development Centre, Derbyshire Children's' Hospital, Nottingham, UK. richard.morton@sdah-tr.trent.nhs.uk
Hankinson
J
J
Nicholson
J
J
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D002547:Cerebral Palsy / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D005544:Forecasting; D006801:Humans; D007273:Injections, Intramuscular; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A